O Brien Greene & Co. Inc Takes $31,000 Position in Acurx Pharmaceuticals, Inc. $ACXP

O Brien Greene & Co. Inc purchased a new stake in shares of Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund purchased 60,000 shares of the company’s stock, valued at approximately $31,000. O Brien Greene & Co. Inc owned approximately 0.20% of Acurx Pharmaceuticals at the end of the most recent reporting period.

Analyst Ratings Changes

ACXP has been the subject of a number of recent analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $31.00 price objective on shares of Acurx Pharmaceuticals in a report on Tuesday, September 30th. Wall Street Zen cut shares of Acurx Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Sunday, October 19th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Acurx Pharmaceuticals in a research note on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $31.00.

Acurx Pharmaceuticals Stock Performance

Shares of ACXP stock opened at $5.00 on Friday. The stock has a fifty day moving average price of $5.20 and a 200 day moving average price of $6.91. The stock has a market cap of $7.90 million, a PE ratio of -0.47 and a beta of -1.27. Acurx Pharmaceuticals, Inc. has a 1 year low of $3.80 and a 1 year high of $38.00.

Acurx Pharmaceuticals (NASDAQ:ACXP) last announced its earnings results on Monday, August 11th. The company reported ($1.89) EPS for the quarter, beating analysts’ consensus estimates of ($2.00) by $0.11. As a group, equities research analysts predict that Acurx Pharmaceuticals, Inc. will post -0.89 earnings per share for the current year.

Acurx Pharmaceuticals Profile

Acurx Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.